Daily Mail - - City & Finance -

BIOTECH firm Cir­cas­sia has con­tin­ued to climb fol­low­ing its turn­around deal last week with As­traZeneca.

The com­pany ac­quired rights to sell two of As­tra’s res­pi­ra­tory drugs in the US. An­a­lysts at Stifel Ni­co­laus up­graded Cir­cas­sia to a ‘buy’ rat­ing.

Cir­cas­sia turned to res­pi­ra­tory drugs af­ter its cat al­lergy treat­ment failed clin­i­cal tri­als last year. It is pay­ing As­traZeneca £185m for the rights, while As­tra takes a 14pc stake.

Shares climbed 13pc, or 12p, to 104p.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.